Tag: Portrazza

NICE rejects Lilly’s Portrazza, but backs Bayer’s Xofigo and Amgen’s Imlygic

by Selina McKee | Sep 30, 2016 | News | 0

Cost regulators for the NHS in England and Wales have published final guidelines turning down the use of Eli Lilly’s Portrazza to treat lung cancer, but backing Bayer’s Xofigo for prostate cancer and Amgen’s Imlygic for melanoma.

NICE turns down Lilly’s lung cancer drug Portrazza

by Selina McKee | May 27, 2016 | News | 0

It is looking unlikely that lung cancer patients in England and Wales will get access to Eli Lilly’s new treatment Portrazza on the National Health Service, after the drug received an initial rejection from cost regulators.